GlassScriptPhysician profile
Orlon V Carr
NPI 1144212135
$855.58
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $128.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.44 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $115.92 | 2019-2020 | |
| Pfizer INC. | $88.41 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.03 | 2019-2020 | |
| Intuitive Surgical, INC. | $52.18 | 2020 | |
| Janssen Pharmaceuticals, INC | $51.97 | 2019 | |
| Arbor Pharmaceuticals, INC. | $40.87 | 2019 | |
| Allergan, INC. | $35.57 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.88 | 2019 | |
| Boston Scientific Corporation | $20.79 | 2019 | |
| Glaxosmithkline, LLC. | $19.15 | 2019 | |
| Mission Pharmacal Company | $17.74 | 2019 | |
| Amarin Pharma, INC. | $17.32 | 2019 | |
| Shire North American Group INC | $16.05 | 2019 | |
| Novo Nordisk INC | $15.38 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $11.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orlon Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.